Repligen (RGEN) Tops Q1 EPS by 20c; Lowers FY Outlook
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $176.89 -0.73%
Revenue Growth %: +9.4%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +9.4%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $206.4 million versus the consensus estimate of $185.48 million.
GUIDANCE:
Repligen sees FY2022 EPS of $3.07-$3.15, versus the consensus of $3.25. Repligen sees FY2022 revenue of $770-800 million, versus the consensus of $819.5 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
